Warning: The NCBI web site requires JavaScript to function. more...
Tumor-infiltrating effector cells of alpha-galactosylceramide-induced antitumor immunity in metastatic liver tumor.
Osada T, Nagawa H, Shibata Y.
J Immune Based Ther Vaccines. 2004 Jul 13;2(1):7.
Related citations
Decreased expressions of CD1d molecule on liver dendritic cells in subcutaneous tumor bearing mice.
Tatsumi T, Takehara T, Yamaguchi S, Sasakawa A, Yamamoto M, Fujita Y, Miyagi T, Ohkawa K, Hayashi N.
J Hepatol. 2008 Nov;49(5):779-86. Epub 2008 Jul 2.
Activated liver dendritic cells generate strong acquired immunity in alpha-galactosylceramide treatment.
Sasakawa A, Tatsumi T, Takehara T, Yamaguchi S, Yamamoto M, Ohkawa K, Miyagi T, Hayashi N.
J Hepatol. 2009 Jun;50(6):1155-62. Epub 2009 Feb 26.
Innate Valpha14(+) natural killer T cells mature dendritic cells, leading to strong adaptive immunity.
Fujii S, Shimizu K, Hemmi H, Steinman RM.
Immunol Rev. 2007 Dec;220:183-98. Review.
α-Galactosylceramide activates antitumor immunity against liver tumor.
Tatsumi T, Takehara T, Miyagi T, Sugiyama T, Aketa H, Sasakawa A, Kanto T, Hiramatsu N, Hayashi N.
Hepatol Res. 2011 Feb;41(2):160-9. doi: 10.1111/j.1872-034X.2010.00743.x. Epub 2010 Nov 25.
Essential role of bystander cytotoxic CD122+CD8+ T cells for the antitumor immunity induced in the liver of mice by alpha-galactosylceramide.
Nakagawa R, Inui T, Nagafune I, Tazunoki Y, Motoki K, Yamauchi A, Hirashima M, Habu Y, Nakashima H, Seki S.
J Immunol. 2004 Jun 1;172(11):6550-7.
Neutralization of tumor necrosis factor abrogates hepatic failure induced by alpha-galactosylceramide without attenuating its antitumor effect in aged mice.
Inui T, Nakashima H, Habu Y, Nakagawa R, Fukasawa M, Kinoshita M, Shinomiya N, Seki S.
J Hepatol. 2005 Oct;43(4):670-8.
Tumor cells loaded with alpha-galactosylceramide induce innate NKT and NK cell-dependent resistance to tumor implantation in mice.
Shimizu K, Goto A, Fukui M, Taniguchi M, Fujii S.
J Immunol. 2007 Mar 1;178(5):2853-61.
Therapeutic effect of alpha-galactosylceramide-loaded dendritic cells genetically engineered to express SLC/CCL21 along with tumor antigen against peritoneally disseminated tumor cells.
Matsuyoshi H, Hirata S, Yoshitake Y, Motomura Y, Fukuma D, Kurisaki A, Nakatsura T, Nishimura Y, Senju S.
Cancer Sci. 2005 Dec;96(12):889-96.
Antitumor effect of whole body hyperthermia with alpha-galactosylceramide in a subcutaneous tumor model of colon cancer.
Hattori T, Kokura S, Okuda T, Okayama T, Takagi T, Handa O, Naito Y, Yoshida N, Yoshikawa T.
Int J Hyperthermia. 2007 Nov;23(7):591-8.
Prevention of injury-induced suppression of T-cell immunity by the CD1d/NKT cell-specific ligand alpha-galactosylceramide.
Tulley JM, Palmer JL, Gamelli RL, Faunce DE.
Shock. 2008 Feb;29(2):269-77.
Activation-induced NKT cell hyporesponsiveness protects from alpha-galactosylceramide hepatitis and is independent of active transregulatory factors.
Biburger M, Tiegs G.
J Leukoc Biol. 2008 Jul;84(1):264-79. Epub 2008 Apr 11.
IFN-gamma-mediated inhibition of tumor angiogenesis by natural killer T-cell ligand, alpha-galactosylceramide.
Hayakawa Y, Takeda K, Yagita H, Smyth MJ, Van Kaer L, Okumura K, Saiki I.
Blood. 2002 Sep 1;100(5):1728-33.
alpha-Galactosylceramide-loaded, antigen-expressing B cells prime a wide spectrum of antitumor immunity.
Kim YJ, Ko HJ, Kim YS, Kim DH, Kang S, Kim JM, Chung Y, Kang CY.
Int J Cancer. 2008 Jun 15;122(12):2774-83.
Effects of cyclosporin A on the activation of natural killer T cells induced by alpha-galactosylceramide.
Kajiwara T, Tomita Y, Okano S, Iwai T, Yasunami Y, Yoshikai Y, Nomoto K, Yasui H, Tominaga R.
Transplantation. 2007 Jan 27;83(2):184-92.
Sequential activation of NKT cells and NK cells provides effective innate immunotherapy of cancer.
Smyth MJ, Wallace ME, Nutt SL, Yagita H, Godfrey DI, Hayakawa Y.
J Exp Med. 2005 Jun 20;201(12):1973-85. Erratum in: J Exp Med. 2005 Aug 15;202(4):569.
Alpha-galactosylceramide modulates the induction of indoleamine 2,3-dioxygenase in antigen presenting cells.
Fallarini S, Paoletti T, Panza L, Lombardi G.
Biochem Pharmacol. 2008 Sep 15;76(6):738-50. Epub 2008 Jul 11.
During acute Trypanosoma cruzi infection highly susceptible mice deficient in natural killer cells are protected by a single alpha-galactosylceramide treatment.
Duthie MS, Kahn SJ.
Immunology. 2006 Nov;119(3):355-61. Epub 2006 Jul 26.
Alpha-galactosylceramide-induced liver injury in mice is mediated by TNF-alpha but independent of Kupffer cells.
J Immunol. 2005 Aug 1;175(3):1540-50.
Glycolipid alpha-C-galactosylceramide is a distinct inducer of dendritic cell function during innate and adaptive immune responses of mice.
Fujii S, Shimizu K, Hemmi H, Fukui M, Bonito AJ, Chen G, Franck RW, Tsuji M, Steinman RM.
Proc Natl Acad Sci U S A. 2006 Jul 25;103(30):11252-7. Epub 2006 Jul 14.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on